Yes, I thought about adding at 3.50. It's good I held off because Putin scared me off. Perhaps Monday.
Is it possible the Russians stole the Malaysian plane to create a diversion? Keep the US, India, and China's eyes busy and away from the Black Sea?
Probably because of the bloopers, and the new class of target, and drug against the target. It's not like REGN going after well characterized and proven VEGF target. Investors are being overly cautious with lptn, IMO.
TGTX, is developing a best-in-class anti-CD20 and PI3k inhibitor. Probably would be competing with the established leaders like Roche, yet market cap is at 240M. I'm not complaining since I also loaded up on that one when the manipulators pushed pps down hard.
2014 is when the spotlight will be on LPTN. If what we know and understand about Isonep is accurate, there is no reason pps should not shoot to $40 this year. We wait...
OK, you LPath pumpers. I added some more today. That will be the last one until we hear about the Isonep partner. Hopefully, Lpathomab will bring a big chunk of upfront payment.
At a sell price of 6.71, means the investor is confident that pps should soar ahead of the buy price. Seems like TGTX won't have to do another public offering in 2014.
Why do they have to go to those conferences when they really don't have anything to sell em boys? Why not wait until the Isonep results then hit the circuit? Well, maybe they can sell them boys on LPathomab. Would be nice if a partner suddenly shows interests on that one. Biogen is wasting time and money on those long shot RNAi, when it could partner on LPathomab at this stage.
of the shares traded today already. I am thinking of buying more believing that this should not be going down from here, except if Putin throws a tantrum again. PPS should be back to 5 again soon. Wish me luck.
7:31 am Lpath: New published paper shows efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury models (LPTN) : As published by the Journal of Neuroinflammation (vol. 11, article 37), Lpathomab can be used to reduce the size of a TBI and to improve functional behavioral outcomes in experimental animal models. The antibody works as a molecular sponge by soaking up lysophosphatidic acid (:LPA), a molecule that can damage neurons and promote dangerous inflammatory responses in the central nervous system. In collaboration with scientists at the University of Melbourne, the antibody was tested in mice that had TBIs. A key finding of the study was the significant efficacy of administering Lpathomab after an injury, thus demonstrating a potential therapeutic benefit. Also shown for the first time in this groundbreaking paper was that human patients with TBI exhibited substantial increases in the levels of LPA in the cerebrospinal fluid (:CSF) after injury, a finding also seen in the injured mouse model of TBI; such data suggest that LPA is a valid target for therapeutic intervention......
BIIB ended up getting royalties from Roche. GA101 is Roche's follow up to Rituxan when it goes off patent. TG Therapeutics also has one anti-CD20 that is supposed to be better than Rituxan, and hopefully GA101. TG also has a PI3k candidate. TG has combo studies on their anti-CD20 and pi3k inhibitor. TGTX is still very cheap. And, yes, I am invested and making money right now in TGTX.
And they are now more desperate to increase revenues from Kadcyla...plus the rest of the IMGN pipeline. Therefore, Roche is eyeing to buy IMGN...before 2015. Is that right?
Putin is so crafty that I won't be surprised if I am not far off in speculating that he sold many of his holdings and sold calls before he ordered his troops into Ukraine. He is probably among the top 10 of the world's richest. With the Russian market in doldrums, he knows he can manipulate the world market and make money off Russian people's and the world market's misery.
Good luck to us, ponsi schemer! I hope you are right about the new highs tomorrow morning.
I thought I might play with the FRX wave that might cause ripples in IMGN pps but I was not able to buy this morning below 16. Instead, I looked around and I was able to play with the sell on the news price mvmt of BMRN. Very nice, that one! Made money on some and am keeping the rest for the higher run.